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Autophagy is a catabolic process responsible for the degradation and recycling of long-lived proteins and organelles by lysosomes.
This degradative pathway sustains cell survival during nutrient deprivation, but in some circumstances, autophagy leads to cell
death.Thereby,autophagycanserveastumorsuppressor,asthereductioninautophagiccapacitycausesmalignanttransformation
and spontaneous tumors. On the other hand, this process also functions as a protective cell-survival mechanism against
environmental stress causing resistance to antineoplastic therapies. Although autophagy inhibition, combined with anticancer
agents, could be therapeutically beneﬁcial in some cases, autophagy induction by itself could lead to cell death in some apoptosis-
resistant cancers, indicating that autophagy induction may also be used as a therapy. This paper summarizes the most important
ﬁndings described in the literature about autophagy and also discusses the importance of this process in clinical settings.
1.Autophagy: Basic Concepts
Autophagy is the primary intracellular catabolic process
responsible for long-lived proteins and organelles degrada-
tionandrecycling,whereastheubiquitin/proteosomesystem
is the major cellular pathway responsible for short-lived
proteins degradation [1]. Autophagy is an evolutionarily
conserved mechanism throughout macromolecules, ribo-
somes, and organelles are degraded.
Initial steps include vesicle nucleation (isolation of
the membrane), vesicle elongation, and completion of the
double-membrane vesicle [2]. In autophagy, the cytosolic
elements that must be degraded are sequestrated by an
isolating double-membrane vesicle of nonlysosomal origin
that is sealed, creating an autophagic vacuole or autophago-
some. Fusion of lysosomes with autophagosomes provides
the enzymes required for degradation of sequestrated com-
ponents [3]. The initial phagophores are formed from
the endoplasmic reticulum, and they act surrounding and
packing organelles to form autophagosomes [4]( Figure 1).
Recently, autophagy emerged as a multifunctional path-
way activated in response to microenvironmental stress,
intracellular damage caused by hypoxia, chemotherapeutic
agents,virusinfections,andtoxins.Autophagymayalsohave
a role in cell death, as cancer cells often develop mutations
that confer resistance to apoptosis. Nonapoptotic forms of
programmed cell death (PCD) might be targeted for novel
approaches [5, 6].
2. Physiological Functionsof
Autophagy Process
Autophagy is considered a physiological mechanism that
may serve for temporary cell survival and is triggered by
starvation, such as amino acid and nutrient deprivation,
hypoxia, and metabolic stress [3].
Recent studies have demonstrated the existence of a
nonapoptotic form of programmed death called autophagic
celldeath,whichisnowconsideredasprogrammedcelldeath
(PCD II). Although autophagy was initially described as a
protective mechanism allowing cell survival and generating
nutrients and energy, other studies have demonstrated that
continuous stress can also promote PCD II [2].2 International Journal of Breast Cancer
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Figure 1: Diﬀerent mechanisms to recycle molecules and organelles in the eukaryotic cell. Eukaryotes have two major protein degradation
systems within cells. One is the ubiquitin-proteasome system, which accounts for the selective degradation of most short-lived proteins. The
other is the autophagy, the primary means for the degradation of cytoplasmic constituents in the lysosome.
2.1. Role of Autophagy in Normal Mammary Gland Develop-
ment. Several works have proved that autophagy is impli-
cated in normal mammary gland development.
In mammalian, the mammary gland expresses its
maximum growth potential maturity after pregnancy and
during lactation. The cycle of proliferation-diﬀerentiation-
regression is repeated at each gestation and can be repro-
duced in culture systems in vitro. A deeper understanding
of how growth and diﬀerentiation of the mammary tissue
are regulated can complement the knowledge of the devel-
o p m e n t a lp r o c e s sa sw e l la st h et r e a t m e n ta n dp r e v e n t i o no f
mammary cancers [7].
PCD is an essential physiological process operating at
all stages of mammary gland remodeling. During mammary
gland involution, the extracellular matrix (ECM) and alveo-
lar basement membrane are degraded. Also, the alveoli lose
their structural integrity, and massive death of mammary
epithelial cells is observed. PCD I (apoptosis) is responsible
for cell loss during mammary gland involution [8, 9].
However, there is a lot of evidence suggesting that not only
PCD I, but also PCD II is observed in mammary epithelial
cells.
In vitro and in vivo studies of bovine mammary gland
physiology have revealed that an enhanced process of
a u t o p h a g yi so b s e r v e da tt h ee n do fl a c t a t i o na n dd u r i n gd r y
periods [10, 11]. It is manifested by the increased expression
of Beclin 1 and the higher number of cells with typical
morphological features of autophagy. Furthermore, 3D
modelofbovinemammaryepithelialcellsgrownonMatrigel
showed that during the development and diﬀerentiation of
mammary acini, the level of membrane-bound microtubule-
associated protein chain 3 (LC3) was increased [12, 13]. This
protein is a well-known autophagy marker.
3. Autophagy Marker
The development of targeted small molecule inhibitors, like
those used for PI3K-AKT-mTOR pathway, has presented
a molecular link between the disruption of this signaling
cascadeandtheautophagyprocess.Thecellularconsequence
of stimulating or inhibiting autophagy in cancer cells is not
completely understood, so it is important that this process
be monitored, along with antiproliferative and apoptotic
biomarkers, in the preclinical setting.
LC3 is considered as a speciﬁc autophagy marker [14].
After the synthesis of LC3, this molecule is cleaved to form
LC3-I,anduponinductionofautophagy,LC3-Iisconjugated
tothelipidphosphatidylethanolaminetoformLC3-II,which
is tightly bound to the membrane of the autophagosome
[15]. Immunoblotting assessment of LC3 expression is an
easy method to predict autophagic activity of mammalian
cells, because the amount of LC3-II correlates with the
number of autophagosomes [13, 16–18]. The product of
autophagic conversion of LC3, LC3-II, tightly associates with
the autophagosome membrane and migrates faster than
LC3-I on SDS-PAGE. Therefore, LC3 immunoblotting may
detect two bands: LC3-I with an apparent mobility of 18kDa
and LC3-II with an apparent mobility of 16kDa.International Journal of Breast Cancer 3
4. ControversialRole of Autophagy in
Malignant Transformation
Autophagy could be associated with various pathological
conditions including, cardiomyopathy, muscular diseases,
neurodegenerative disorders, and cancer.
4.1. Autophagy as a Tumor-Suppressor Mechanism. Studies in
diﬀerentcellslineshaveshownthatcancercellsexpresslower
levels of the autophagy-related proteins LC3-II and Beclin 1
than normal epithelial cells [19, 20]. Besides, while heterozy-
gous disruption of BECN1 gene promotes tumor develop-
ment [19], the overexpression inhibits tumorigenesis [21],
supporting the idea that defective autophagy or autophagy
inhibition plays a role in malignant transformation. BECN1
gene is deleted in about 50% of breast cancers [21, 22]. In
addition, reduced expression of Beclin1 has been reported
in other types of cancers such as colon and brain tumors
[23, 24]. Overall, the data suggest that a defective autophagic
process is clearly linked to cancer development.
The most important evidence linking dysfunctional
autophagy and cancer comes from studies demonstrating
that autophagy inhibition in mice, by disruption of BECN1,
increases cellular proliferation as well as mammary hyper-
plasia and accelerates tumor development. In addition,
transfection of MCF-7 breast cancer cells, that express low
levels of Beclin 1, with BECN1 gene, inhibits growth and
tumor formation [21]. These results suggest that Beclin 1 is a
haploinsuﬃcient tumor suppressor and defective autophagy
may be critical for cells malignant transformation [19].
In contrast to apoptosis, PCD II, in general, is caspase
independent, does not involve classic DNA laddering, and is
believedtobearesultofanextensiveautophagicdegradation
of intracellular content [25]. Studies also suggest that
apoptosis and autophagy are linked by eﬀectors proteins
(e.g., Bcl-2, Bcl-XL, Mcl-1, ATG5, and p53) and common
pathways (e.g., PI3K/Akt/mTOR, NFκB, and ERK) [5, 26,
27]. For example, p53 activation triggers starvation response
in primary mouse embryonic ﬁbroblasts, which is marked
by activation of AMPK (AMP-activated kinase) that inhibits
mTOR pathway. In other tissues and cells, p53 may commu-
nicate with mTOR pathway by the upregulation of the PTEN
and TSC2 genes [28].
There is evidence that autophagy may function as a PCD
II in cancer cells in which apoptosis is defective or hard
to induce [29]. Therefore, it is reasonable to propose that
the induction of autophagic cell death may be used as a
therapeutic strategy for cancer treatment.
4.2. Autophagy as a Survival and Drugs-Resistance Mech-
anism. The physiological function of autophagy is related
to the maintenance of cellular homeostasis under cellular
stress. Utilizing autophagy as a survival mechanism in the
severe tumor microenvironment, which is highly hypoxic
and acidic, may favor the development of cancer cells.
It was observed that a high number of antineoplastic
therapies, radiation therapy, chemotherapy (e.g., doxo-
rubicin, temozolomide, and etoposide), histone deacety-
lase inhibitors, arsenic trioxide, TNFα,I F N γ, imatinib,
rapamycin, and antiestrogen hormonal therapy (e.g., tamox-
ifen) induce autophagy, and this induction act as a protective
and prosurvival mechanism in human cancer cell lines [20].
In fact, the therapeutic eﬃcacy of these agents can be
increased if autophagy is inhibited [30–35]. Other studies
have shown that a tumor necrosis factor (TNF) family
ligand-tumor necrosis factor-related apoptosis-inducing lig-
and (TRAIL), induces autophagy in epithelial cells and
that TRAIL inhibition promotes luminal ﬁlling, when it
is combined with Bcl-xL-mediated inhibition of apoptosis
[36].
Altogether,disruptionofautophagyisinvolvedindiverse
human diseases including cancer. In particular, the reg-
ulation of autophagy in cancer cells is complex, since it
can enhance tumor cell survival in response to certain
stresses, but it can also act to suppress the initiation of
tumor growth. In contrast to its protective role, inhibition
of autophagy through speciﬁc gene inactivation can promote
tumorigenesis [2].
5. Autophagy asa Therapeutic Target in
Cancer Patients
Autophagy,whichcouldbeeithercytoprotectiveorcytotoxic,
is often observed in tumor cells in response to chemotherapy
[49]( Table 1).
Mutations or allelic loss of Beclin 1 is frequently found in
breast,ovarian,andprostatecancer[9,10].Beclin1provided
the ﬁrst connection between cancer and autophagy [2]. It
has been suggested that autophagy plays an important role
in chemoresistance of cancer to some therapeutic agents that
typically induce an apoptotic response [39].
5.1. Role of Autophagy in Resistance to Therapy
5.1.1. Autophagy in Breast Cancer Treatment: Endocrine
Therapy and Endocrine Resistance. Endocrine therapy is
administered as an antiestrogen (AE) like Tamoxifen (TAM)
or Fulvestrant (FAS; Faslodex; ICI 182,780) or as aromatase
inhibitor (AI) such as Letrozole or Exemestane. It is less
toxic and potentially more eﬀective therapy in management
of hormone-dependent breast cancers. Antiestrogens, and
TAM in particular, have been the “gold standard” ﬁrst-
line endocrine therapy for over 30 years [50]. It is likely
that the clinical experience with this drug exceeds 15
million patient years [51]. Moreover, TAM is the only single
a g e n tw i t hd e m o n s t r a t e de ﬃcacy in both premenopausal
and postmenopausal women with invasive breast cancer.
Unfortunately, until nowadays, the inability of endocrine
therapies to cure many women with ER+ disease remains.
The precise mechanism by which breast cancer cells
die following estrogen withdrawal (or AI treatment) or AE
treatment is unclear. For example breast cancer cells respond
to AEs and to estrogen withdrawal even if they have a
mutated p53 [52, 53]. Although cell death is one of the
apoptosis endpoints, there are earlier events initiated by
autophagy signals that could be explaining these treatment
responses [53].4 International Journal of Breast Cancer
Table 1: Chemotherapeutic agents involved in autophagy induc-
tion.
Target Drugs and reference
Akt GSK69O693 [37]
Akt Perifosine [37]
Akt Triciribine [37]
AMPK AICAR [38]
AMPK Metformin [39, 40]
Bcr-Abl Imatinib [41]
BNIP3 Arsenic trioxide [42]
CamKK EB1089 (vitamin D) [43]
HDAC SAHA [39]
mTORC1 Amiodarone [44]
mTORC1 Curcumin [45]
mTORC1 Everolimus [46]
mTORC1 Niclosamide [44]
mTORC1 Perhexiline [44]
mTORC1 Rottlerin [44]
mTORC1 Temsirolimus [47]
VEGF Sorafenib [48]
Autophagy has been implicated by the induction of
this mechanism in response to endocrine therapy. Recent
studies showed that endocrine therapy modiﬁes the number
of autophagosomes, increases LC3 protein cleavage, and
reduces expression of p62 [54]. Consistent with other
reports, PCD II is associated with the growth inhibitory
eﬀectsofendocrinetherapyinbreastcancercells[32,55,56].
It remains unclear whether autophagy or apoptosis
dominatesasthecell-deathmechanismorwhetherthisvaries
among diﬀerent breast cancer cells.
While there is currently no deﬁnitive understanding of
the primary cell-death mechanisms either in experimental
models or breast tumors in women about the relative
importance of endocrine therapy-induced changes in pro-
liferation, there are potentially important implications for
the underlying biology of the cancer cells. If the primary
driver of response as seen in tumor shrinkage is a reduction
in proliferation, this will leave many cells alive and still
metabolically active. Surviving cells have the ability to adapt
to the endocrine-induced stress and eventually overcome the
proliferative blockade and grow so that, they will become
resistant [57–59]. It is quite possible that autophagy allows
breast cancer cells to adapt to endocrine-induced stress
and survive. Evidence showed that inhibition of autophagy
sensitizes breast cancer cells to TAM [32].
5.1.2. The Role of Autophagy in Bortezomib Treatment against
Breast Cancer. The 26S proteasomes are multicatalytic pro-
tease complexes consisting of a 20S catalytic core and a
regulator 19S subunit responsible for most nonlysosomal
intracellular degradation [60]. The dipeptide boronic acid
Bortezomib is a selective and potent inhibitor of the
26S proteasome that reversibly inhibits the proteasomal
chymotrypsin-like activity [60, 61].
The inhibition of the 26S proteasome by Bortezomib
may lead to the accumulation and aggregation of misfolded
proteins in the endoplasmic reticulum lumen resulting
in the activation of an unfolded protein response (UPR)
through the action of three key endoplasmic reticulum-
resident transmembrane proteins, pERK, IRE1, and ATF6
[62–64]. The activated protein pERK is a member of a
family of protein kinases that phosphorylates the subunit of
the cytosolic eukaryotic translation initiation factor eIF2a,
resulting in a reduced global protein synthesis and in a pref-
erential translation of selected mRNAs including activating
transcription factor 4 (ATF4) [63, 64]. Some reports have
identiﬁed endoplasmic reticulum stress and the eIF2a/pERK
pathway as potent inducers of macroautophagy where it
promotes cell survival [65–67].
A recent study in MCF7 cell line showed that during
Bortezomib treatment, LC3B protein and mRNA levels
increased signiﬁcantly in a dose and time-dependent man-
ner. The increase of autophagy in Bortezomib-treated cells
was dependent on upregulation of LC3B by ATF4 [68]. In
addition,MCF7cellstransfectedwithRNAispeciﬁctoLC3B,
ATF4,orpERKweremoresensitivetoBortezomibtreatment.
Furthermore, the loss of LC3B or ATF4 was associated with
a signiﬁcant increase in dead cells staining for both Annexin
V and propidium iodide after 48 and 72 hours of treatment
[68].
From a clinical point of view, it would be an attractive
possibility to target autophagy to enhance the response of
breast cancer to Bortezomib and sensitize to environmental
stress that normally occurs in solid tumors.
However, clinical experience with Bortezomib has shown
limited activity against breast cancer when used as a single
agent [61].
5.1.3. The Role of Autophagy in Trastuzumab Treatment
againstBreastCancer. Trastuzumab(TzbandHerceptin)was
the ﬁrst immunotherapeutic drug for the treatment of breast
carcinomas overexpressing the HER2 (erbB-2) oncogene
that was successful [69–73]; however, the mechanisms that
could explain de novo and acquired resistance to anti-HER2
monoclonal are not well understood. Proposed mechanisms
for innate or acquired resistance to Tzb include steric
inhibition of Tzb binding to the extracellular domain (ECD)
of the HER2 tyrosine kinase receptor imposed by other
extracellularfactorssuchastheglycoproteinmucin4(MUC-
4) [74, 75].
Recent work showed that Tzb-resistant HER2-positive
breast cancer cells (SKBR3 cell line) exhibit increased
basal autophagy through an increase in LC3-II expression
compared to Tzb-na¨ ıve SKBR3 parental cells, suggesting
that acquired Tzb autoresistance of Tzb-conditioned cells
is accompanied by increased autophagy. Furthermore, inhi-
bition of formation of preautophagosomal structure upon
treatment with 3-methyladenime (3-MA), a pharmacolog-
ical inhibitor of autophagy, notably reduced cell viability
in Tzb-resistant HER2-positive breast cancer cells but not
in Tzb-na¨ ıve SKBR3 parental cells [76]. To provide addi-
tional evidence that autophagy plays a critical survival role
in enabling Tzb-insensitive high-rates of cell proliferationInternational Journal of Breast Cancer 5
in Tzb-refractory cells, the potent and highly sequence-
speciﬁc mechanism of RNA interference (RNAi) was used to
block LC3-dependent autophagosome formation. This assay
avoided any oﬀ-target side eﬀects that may confound inter-
pretation of the results obtained with autophagy inhibitors,
showed that TzbR cells were extremely fragile [76]. These
ﬁndings, altogether, clearly established that hyperactivation
o fb a s a la u t o p h a g yp l a y sa ne s s e n t i a ls u r v i v a lr o l ei nT z b -
refractory TzbR cells rechallenged with Tzb. Therefore,
the Tzb combination with autophagy inhibitors may be
a promising strategy in patients resistant to therapy with
Trastuzumab.
5.2. Role of Autophagy in the Enhancement of the Inhibitory
Eﬀect of Breast Cancer Treatments
5.2.1. Autophagy Enhances the Inhibitory Eﬀect of Paclitaxel
through ARHI Expression. ARHI encodes a small GTP-
bindingproteinbelongingtotheRas/Rapsuperfamily,which
has the characteristics of a tumor suppressor gene in ovarian
and breast cancers, despite sharing 54–59% homology with
Ras proto-oncogenes [77], ARHI is expressed in normal
breast epithelial cells, but in more than 70% of breast
cancers, it is dramatically downregulated. Loss of ARHI
expression has been linked to tumor progression from in
situ to invasive cancer [78]. Paclitaxel, a cytotoxic drug, can
inhibit cancer cell growth by inducing apoptosis and G2/M
cell-cyclearrest.TSA,anHDACinhibitor,canactivateseveral
tumor suppressor genes and induces autophagy.
RecentevidenceshowedthatARHIinduces autophagyin
breastcancercells.SKBR3andMDA-MB231cells,expressing
low levels of endogenous ARHI transfected with ARHI, had
an increase of LC3 punctate number, which represent the
accumulation of LC3 membrane-bound form on autophagic
vesicles. Furthermore, it has been observed that TSA treat-
ment enhanced autophagy, but transfection with siRNA-
ARHI blocked the eﬀects of TSA, demonstrating that ARHI
is essential for autophagy induction [79].
Other results from the same group showed that TSA
greatly enhanced the inhibitory eﬀect of paclitaxel and
tumors treated with a combination of ARHI and paclitaxel
grew signiﬁcantly more slowly than controls, whereas the
individual treatments did not signiﬁcantly inhibit tumor
growth [79].
6. Conclusion andPerspectives
We can conclude that autophagy regulation may provide
a useful tool to prevent cancer development, limit tumor
progression, and increase the eﬃciency of cancer treatment.
Thisautophagyregulationhastobecontextdependent,since
an autophagy process increased may be necessary to prevent
tumor development in individuals at high risk of cancer. But
autophagy activity must be reduced when tumor is already
established and subjected to the environmental stresses
associated with limited angiogenesis, nutrient deprivation,
and hypoxia.
Understanding the signaling pathways involved in
autophagy regulation represents a new direction in the
development of anticancer therapies. However, the proteins
and traﬃcking mechanisms involved in the autophagosomal
maturation step are not completely understood.
The eﬀectiveness of chemotherapeutics is diminished by
the fact that they induce toxicity to both normal and cancer
cells.Manytargetedtherapiesstudieshavebeenconductedto
new drugs development with higher therapeutic index. Cur-
rently, signaling transduction pathways, tumor angiogenesis,
and malignant stem cells are considered prime targets for
new therapeutics development.
References
[1] Y. Fujishima, S. Nishiumi, A. Masuda et al., “Autophagy in
the intestinal epithelium reduces endotoxin-induced inﬂam-
matory responses by inhibiting NF-κB activation,” Archives of
Biochemistry and Biophysics, 2011.
[2] S. Turcotte and A. J. Giaccia, “Targeting cancer cells through
autophagy for anticancer therapy,” Current Opinion in Cell
Biology, vol. 22, no. 2, pp. 246–251, 2010.
[ 3 ]D .J .K l i o n s k ya n dS .D .E m r ,“ A u t o p h a g ya sar e g u l a t e d
pathway of cellular degradation,” Science, vol. 290, no. 5497,
pp. 1717–1721, 2000.
[4] B. Levine and D. J. Klionsky, “Development by self-
digestion: molecular mechanisms and biological functions of
autophagy,” Developmental Cell, vol. 6, no. 4, pp. 463–477,
2004.
[5] S. Shimizu, T. Kanaseki, N. Mizushima et al., “Role of Bcl-2
family proteins in a non-apoptopic programmed cell death
dependent on autophagy genes,” Nature Cell Biology, vol. 6,
no. 12, pp. 1221–1228, 2004.
[6] T. Shintani and D. J. Klionsky, “Autophagy in health and
disease: a double-edged sword,” Science, vol. 306, no. 5698, pp.
990–995, 2004.
[7] F. Borellini and T. Oka, “Growth control and diﬀerentiation in
mammary epithelial cells,” Environmental Health Perspectives,
vol. 80, pp. 85–99, 1989.
[ 8 ]L .H .Q u a r r i e ,C .V .P .A d d e y ,a n dC .J .W i l d e ,“ A p o p t o s i s
in lactating and involuting mouse mammary tissue demon-
strated by nick-end DNA labelling,” Cell and Tissue Research,
vol. 281, no. 3, pp. 413–419, 1995.
[ 9 ]L .H .Q u a r r i e ,C .V .P .A d d e y ,a n dC .J .W i l d e ,“ P r o g r a m m e d
cell death during mammary tissue involution induced by
weaning, litter removal, and milk stasis,” Journal of Cellular
Physiology, vol. 168, no. 3, pp. 559–569, 1996.
[10] J. Zarzy´ nska, B. Gajkowska, U. Wojew´ odzka, E. Dymnicki,
and T. Motyl, “Apoptosis and autophagy in involuting bovine
mammary gland is accompanied by up-regulation of TGF-β1
and suppression of somatotropic pathway,” Polish Journal of
Veterinary Sciences, vol. 10, no. 1, pp. 1–9, 2007.
[11] T. Motyl, M. Gajewska, J. Zarzynska, A. Sobolewska, and B.
Gajkowska, “Regulation of autophagy in bovine mammary
epithelial cells,” Autophagy, vol. 3, no. 5, pp. 484–486, 2007.
[12] M. Gajewska, A. Sobolewska, M. Kozlowski, and T. Motyl,
“Role of autophagy in mammary gland development,” Journal
of Physiology and Pharmacology, vol. 59, supplement 9, pp.
237–249, 2008.
[13] N. Mizushima and T. Yoshimori, “How to interpret LC3
immunoblotting,” Autophagy, vol. 3, no. 6, pp. 542–545, 2007.
[14] Y. Kabeya, N. Mizushima, T. Ueno et al., “LC3, a mammalian
homologue of yeast Apg8p, is localized in autophagosome
membranes after processing,” EMBO Journal, vol. 19, no. 21,
pp. 5720–5728, 2000.6 International Journal of Breast Cancer
[ 1 5 ]S .V .H o l t ,B .W y s p i a n s k a ,K .J .R a n d a l l ,D .J a m e s ,J .R .F o s t e r ,
and R. W. Wilkinson, “The development of an immunohis-
tochemical method to detect the autophagy associated protein
LC3-IIinhumantumorxenografts,”ToxicologicPathology,vol.
39, no. 3, pp. 516–523, 2011.
[16] D.J.Klionsky,H.Abeliovich,P.Agostinisetal.,“Guidelinesfor
the use and interpretation of assays for monitoring autophagy
in higher eukaryotes,” Autophagy, vol. 4, no. 2, pp. 151–175,
2008.
[17] I.Tanida,N.Minematsu-Ikeguchi,T.Ueno,andE.Kominami,
“Lysosomal turnover, but not a cellular level, of endogenous
LC3 is a marker for autophagy,” Autophagy,v o l .1 ,n o .2 ,p p .
84–91, 2005.
[18] S. Kimura, N. Fujita, T. Noda, and T. Yoshimori, “Monitoring
autophagy in mammalian cultured cells through the dynamics
of LC3,” Methods in Enzymology, vol. 451, pp. 1–12, 2009.
[19] X. Qu, J. Yu, G. Bhagat et al., “Promotion of tumorigenesis
by heterozygous disruption of the beclin 1 autophagy gene,”
Journal of Clinical Investigation, vol. 112, no. 12, pp. 1809–
1820, 2003.
[20] Y. Kondo, T. Kanzawa, R. Sawaya, and S. Kondo, “The role of
autophagy in cancer development and response to therapy,”
Nature Reviews Cancer, vol. 5, no. 9, pp. 726–734, 2005.
[21] X. H. Liang, S. Jackson, M. Seaman et al., “Induction of
autophagy and inhibition of tumorigenesis by beclin 1,”
Nature, vol. 402, no. 6762, pp. 672–676, 1999.
[22] V. M. Aita, X. H. Liang, V. V. V. S. Murty et al., “Cloning
and genomic organization of beclin 1, a candidate tumor
suppressor gene on chromosome 17q21,” Genomics, vol. 59,
no. 1, pp. 59–65, 1999.
[23] K. Koneri, T. Goi, Y. Hirono, K. Katayama, and A. Yamaguchi,
“Beclin 1 gene inhibits tumor growth in colon cancer cell
lines,” Anticancer Research, vol. 27, no. 3 B, pp. 1453–1457,
2007.
[24] C. Miracco, E. Cosci, G. Oliveri et al., “Protein and mRNA
expression of autophagy gene Beclin 1 in human brain
tumours,” International Journal of Oncology,v o l .3 0 ,n o .2 ,p p .
429–436, 2007.
[25] T. Kirisako, M. Baba, N. Ishihara et al., “Formation process of
autophagosomeistracedwithApg8/Aut7pinyeast,”Journalof
Cell Biology, vol. 147, no. 2, pp. 435–446, 1999.
[26] L. Moretti, A. Attia, K. W. Kim, and B. Lu, “Crosstalk between
Bak/bax and mTOR signaling regulates radiation-induced
autophagy,” Autophagy, vol. 3, no. 2, pp. 142–144, 2007.
[27] S. Youseﬁ, R. Perozzo, I. Schmid et al., “Calpain-mediated
cleavage of Atg5 switches autophagy to apoptosis,” Nature Cell
Biology, vol. 8, no. 10, pp. 1124–1132, 2006.
[28] Z. Feng, H. Zhang, A. J. Levine, and S. Jin, “The coordinate
regulation of the p53 and mTOR pathways in cells,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 102, no. 23, pp. 8204–8209, 2005.
[29] U. Akar, B. Ozpolat, K. Mehta, J. Fok, Y. Kondo, and G.
Lopez-Berestein, “Tissue transglutaminase inhibits autophagy
in pancreatic cancer cells,” Molecular Cancer Research, vol. 5,
no. 3, pp. 241–249, 2007.
[30] S. Paglin, T. Hollister, T. Delohery et al., “A novel response of
cancer cells to radiation involves autophagy and formation of
acidic vesicles,” Cancer Research, vol. 61, no. 2, pp. 439–444,
2001.
[ 3 1 ]P .B o y a ,R .A .G o n z ´ alez-Polo, N. Casares et al., “Inhibition
of macroautophagy triggers apoptosis,” Molecular and Cellular
Biology, vol. 25, no. 3, pp. 1025–1040, 2005.
[32] M. A. Qadir, B. Kwok, W. H. Dragowska et al., “Macroau-
tophagyinhibitionsensitizestamoxifen-resistantbreastcancer
cells and enhances mitochondrial depolarization,” Breast
Cancer Research and Treatment, vol. 112, no. 3, pp. 389–403,
2008.
[33] J. S. Carew, S. T. Nawrocki, C. N. Kahue et al., “Targeting
autophagy augments the anticancer activity of the histone
deacetylase inhibitor SAHAto overcome Bcr-Abl-mediated
drug resistance,” Blood, vol. 110, no. 1, pp. 313–322, 2007.
[34] R. K. Amaravadi, D. Yu, J. J. Lum et al., “Autophagy inhibition
enhances therapy-induced apoptosis in a Myc-induced model
of lymphoma,” Journal of Clinical Investigation, vol. 117, no. 2,
pp. 326–336, 2007.
[35] M. J. Abedin, D. Wang, M. A. McDonnell, U. Lehmann, and
A. Kelekar, “Autophagy delays apoptotic death in breast cancer
cells following DNA damage,” Cell Death and Diﬀerentiation,
vol. 14, no. 3, pp. 500–510, 2007.
[36] K. R. Mills, M. Reginato, J. Debnath, B. Queenan, and J.
S. Brugge, “Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is required for induction of autophagy
during lumen formation in vitro,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 101,
no. 10, pp. 3438–3443, 2004.
[37] D.Kim,G.Z.Cheng,C.W.Lindsley,H.Yang,andJ.Q.Cheng,
“Targeting the phosphatidylinositol-3 kinase/Akt pathway for
the treatment of cancer,” Current Opinion in Investigational
Drugs, vol. 6, no. 12, pp. 1250–1258, 2005.
[38] D. Meley, C. Bauvy, J. H. P. M. Houben-Weerts et al., “AMP-
activated protein kinase and the regulation of autophagic
proteolysis,” Journal of Biological Chemistry, vol. 281, no. 46,
pp. 34870–34879, 2006.
[39] J. S. Carew, S. T. Nawrocki, and J. L. Cleveland, “Modulating
autophagy for therapeutic beneﬁt,” Autophagy, vol. 3, no. 5,
pp. 464–467, 2007.
[40] M. Buzzai, R. G. Jones, R. K. Amaravadi et al., “Systemic
treatment with the antidiabetic drug metformin selectively
impairs p53-deﬁcient tumor cell growth,” Cancer Research,
vol. 67, no. 14, pp. 6745–6752, 2007.
[41] G. Yogalingam and A. M. Pendergast, “Abl kinases regulate
autophagy by promoting the traﬃcking and function of
lysosomal components,” Journal of Biological Chemistry, vol.
283, no. 51, pp. 35941–35953, 2008.
[42] T. Kanzawa, L. Zhang, L. Xiao, I. M. Germano, Y. Kondo, and
S. Kondo, “Arsenic trioxide induces autophagic cell death in
malignant glioma cells by upregulation of mitochondrial cell
death protein BNIP3,” Oncogene, vol. 24, no. 6, pp. 980–991,
2005.
[43] M. Høyer-Hansen, L. Bastholm, P. Szyniarowski et al., “Con-
trol of macroautophagy by calcium, calmodulin-dependent
kinase kinase-β, and Bcl-2,” Molecular Cell,v o l .2 5 ,n o .2 ,p p .
193–205, 2007.
[44] A. D. Balgi, B. D. Fonseca, E. Donohue et al., “Screen for
chemical modulators of autophagy reveals novel therapeutic
inhibitors of mTORC1 signaling,” PLoS ONE, vol. 4, no. 9,
article e7124, 2009.
[ 4 5 ]C .S .B e e v e r s ,L .C h e n ,L .L i u ,Y .L u o ,N .J .G .W e b s t e r ,
and S. Huang, “Curcumin disrupts the mammalian target of
rapamycin-raptor complex,” Cancer Research, vol. 69, no. 3,
pp. 1000–1008, 2009.
[46] C. Cao, T. Subhawong, J. M. Albert et al., “Inhibition of
mammaliantargetofrapamycinorapoptoticpathwayinduces
autophagy and radiosensitizes PTEN null prostate cancer
cells,” Cancer Research, vol. 66, no. 20, pp. 10040–10047, 2006.
[ 4 7 ] V .Y .Y a z b e c k ,D .B u g l i o ,G .V .G e o r g a k i se ta l . ,“ T e m s i r o l i m u s
downregulates p21 without altering cyclin D1 expression and
induces autophagy and synergizes with vorinostat in mantleInternational Journal of Breast Cancer 7
cell lymphoma,” Experimental Hematology,v o l .3 6 ,n o .4 ,p p .
443–450, 2008.
[ 4 8 ]M .A .P a r k ,G .Z h a n g ,A .P .M a r t i ne ta l . ,“ V o r i n o s t a ta n d
sorafenib increase ER stress, autophagy and apoptosis via
ceramide-dependent CD95 and PERK activation,” Cancer
Biology and Therapy, vol. 7, no. 10, pp. 1648–1662, 2008.
[49] P. M. Yang and C. C. Chen, “Life or death? Autophagy
in anticancer therapies with statins and histone deacetylase
inhibitors,” Autophagy, vol. 7, no. 1, pp. 107–108, 2011.
[50] M.P.Cole,C.T.Jones,andI.D.Todd,“Anewanti-oestrogenic
agent in late breast cancer. An early clinical appraisal of
ICI46474,” British Journal of Cancer, vol. 25, no. 2, pp. 270–
275, 1971.
[51] R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar, “Cellular
and molecular pharmacology of antiestrogen action and
resistance,” Pharmacological Reviews, vol. 53, no. 1, pp. 25–71,
2001.
[ 5 2 ]R .B .R i g g i n s ,A .H .B o u t o n ,M .C .L i u ,a n dR .C l a r k e ,
“Antiestrogens, aromatase inhibitors, and apoptosis in breast
cancer,” Vitamins and Hormones, vol. 71, pp. 201–237, 2005.
[53] K. B. Bouker, T. C. Skaar, D. R. Fernandez et al., “Interferon
regulatory factor-1 mediates the proapoptotic but not cell
cycle arrest eﬀects of the steroidal antiestrogen ICI 182,780
(Faslodex, Fulvestrant),” Cancer Research, vol. 64, no. 11, pp.
4030–4039, 2004.
[54] N. T¨ or¨ o k ,R .U r r u t i a ,T .N a k a m u r a ,a n dM .A .M c N i v e n ,
“Upregulation of molecular motor-encoding genes during
hepatocyte growth factor-and epidermal growth factor-
induced cell motility,” Journal of Cellular Physiology, vol. 167,
no. 3, pp. 422–433, 1996.
[55] B. Inbal, S. Bialik, I. Sabanay, G. Shani, and A. Kimchi,
“DAP kinase and DRP-1 mediate membrane blebbing and
the formation of autophagic vesicles during programmed cell
death,” Journal of Cell Biology, vol. 157, no. 3, pp. 455–468,
2002.
[56] R. Clarke, A. N. Shajahan, R. B. Riggins et al., “Gene network
signaling in hormone responsiveness modiﬁes apoptosis and
autophagy in breast cancer cells,” Journal of Steroid Biochem-
istry and Molecular Biology, vol. 114, no. 1-2, pp. 8–20, 2009.
[57] N. Brunner, T. L. Frandsen, C. Holst-Hansen et al.,
“MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast
cancervariantthatretainssensitivitytothesteroidalantiestro-
gen ICI 182,780,” Cancer Research, vol. 53, no. 14, pp. 3229–
3232, 1993.
[58] N. Br¨ unner, B. Boysen, S. Jirus et al., “MCF7/LCC9: an
antiestrogen-resistant MCF-7 variant in which acquired resis-
tance to the steroidal antiestrogen ICI 182,780 confers an early
cross- resistance to the nonsteroidal antiestrogen tamoxifen,”
Cancer Research, vol. 57, no. 16, pp. 3486–3493, 1997.
[59] N. Brunner, V. Boulay, A. Fojo, C. E. Freter, M. E. Lippman,
and R. Clarke, “Acquisition of hormone-independent growth
in MCF-7 cells is accompanied by increased expression
of estrogen-regulated genes but without detectable DNA
ampliﬁcations,” Cancer Research, vol. 53, no. 2, pp. 283–290,
1993.
[60] J. Adams, V. J. Palombella, E. A. Sausville et al., “Proteasome
inhibitors: a novel class of potent and eﬀective antitumor
agents,” Cancer Research, vol. 59, no. 11, pp. 2615–2622, 1999.
[ 6 1 ]T .C a r a v i t a ,P .d eF a b r i t i i s ,A .P a l u m b o ,S .A m a d o r i ,a n d
M. Boccadoro, “Bortezomib: eﬃcacy comparisons in solid
tumors and hematologic malignancies,” Nature Clinical Prac-
tice Oncology, vol. 3, no. 7, pp. 374–387, 2006.
[62] S. T. Nawrocki, J. S. Carew, M. S. Pino et al., “Bortezomib
sensitizes pancreatic cancer cells to endoplasmic reticulum
stress-mediated apoptosis,” Cancer Research, vol. 65, no. 24,
pp. 11658–11666, 2005.
[63] T. Rzymski and A. L. Harris, “The unfolded protein response
and integrated stress response to anoxia,” Clinical Cancer
Research, vol. 13, no. 9, pp. 2537–2540, 2007.
[64] H. P. Harding, Y. Zhang, and D. Ron, “Protein translation and
folding are coupled by an endoplasmic- reticulum-resident
kinase,” Nature, vol. 397, no. 6716, pp. 271–274, 1999.
[65] T. Yorimitsu and D. J. Klionsky, “Endoplasmic reticulum
stress: a new pathway to induce aytophagy,” Autophagy, vol.
3, no. 2, pp. 160–162, 2007.
[ 6 6 ]T .Y o r i m i t s u ,U .N a i r ,Z .Y a n g ,a n dD .J .K l i o n s k y ,“ E n d o p l a s -
mic reticulum stress triggers autophagy,” Journal of Biological
Chemistry, vol. 281, no. 40, pp. 30299–30304, 2006.
[67] Y. Kouroku, E. Fujita, I. Tanida et al., “ER stress (PERK/eIF2α
phosphorylation) mediates the polyglutamine-induced LC3
conversion, an essential step for autophagy formation,” Cell
Death and Diﬀerentiation, vol. 14, no. 2, pp. 230–239, 2007.
[68] M. Milani, T. Rzymski, H. R. Mellor et al., “The role of ATF4
stabilization and autophagy in resistance of breast cancer cells
treated with Bortezomib,” Cancer Research, vol. 69, no. 10, pp.
4415–4423, 2009.
[69] M. D. Pegram, G. Konecny, and D. J. Slamon, “The
molecular and cellular biology of HER2/neu gene ampliﬁca-
tion/overexpression and the clinical development of herceptin
(trastuzumab) therapy for breast cancer,” Cancer Treatment
and Research, vol. 103, pp. 57–75, 2000.
[70] K. H. Lan, C. H. Lu, and D. Yu, “Mechanisms of trastuzumab
resistance and their clinical implications,” Annals of the New
York Academy of Sciences, vol. 1059, pp. 70–75, 2005.
[71] R. Nahta and F. J. Esteva, “Herceptin: mechanisms of action
and resistance,” Cancer Letters, vol. 232, no. 2, pp. 123–138,
2006.
[72] R. Nahta, D. Yu, M. C. Hung, G. N. Hortobagyi, and F.
J. Esteva, “Mechanisms of disease: understanding resistance
to HER2-targeted therapy in human breast cancer,” Nature
Clinical Practice Oncology, vol. 3, no. 5, pp. 269–280, 2006.
[73] R. Nahta and F. J. Esteva, “Trastuzumab: triumphs and
tribulations,” Oncogene, vol. 26, no. 25, pp. 3637–3643, 2007.
[74] S. A. Price-Schiavi, S. Jepson, P. Li et al., “Rat MUC4 (sialo-
mucin complex) reduces binding of anti-ErbB2 antibodies
to tumor cell surfaces, a potential mechanism for herceptin
resistance,” International Journal of Cancer,v o l .9 9 ,n o .6 ,p p .
783–791, 2002.
[75] P. Nagy, E. Friedl¨ ander, M. Tanner et al., “Decreased accessi-
bility and lack of activation of ErbB2 in JIMT-1, a herceptin-
resistant, MUC4-expressing cancer cell line,” Cancer Research,
vol. 65, no. 2, pp. 473–482, 2005.
[76] A. Vazquez-Martin, C. Oliveras-Ferraros, and J. A. Menendez,
“Autophagy facilitates the development of breast cancer resis-
tance to the anti-HER2 monoclonal antibody trastuzumab,”
PLoS ONE, vol. 4, no. 7, article e6251, 2009.
[77] Y. Yu, F. Xu, H. Peng et al., “NOEY2 (ARHI), an imprinted
putative tumor suppressor gene in ovarian and breast carci-
nomas,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 96, no. 1, pp. 214–219, 1999.
[78] L. Wang, A. Hoque, R. Z. Luo et al., “Loss of the expression
of the tumor suppressor gene ARHI is associated with
progression of breast cancer,” Clinical Cancer Research, vol. 9,
no. 10 I, pp. 3660–3666, 2003.
[79] C. F. Zou, L. Jia, H. Jin et al., “Re-expression of ARHI
(DIRAS3) induces autophagy in breast cancer cells and
enhances the inhibitory eﬀect of paclitaxel,” BMC Cancer, vol.
11, p. 22, 2011.